Good response of an aggressive rare variant of signet ring cell carcinoma of prostate with hormonal therapy.

Related Articles

Good response of an aggressive rare variant of signet ring cell carcinoma of prostate with hormonal therapy.

BMJ Case Rep. 2017 Mar 08;2017:

Authors: Tiwari D, Nayak B, Seth A

Abstract
Primary signet ring cell carcinoma (SRCC) of the prostate is a rare entity, characterised by its aggressive nature and dismal prognosis. We report a case of an advanced SRCC of the prostate presenting as a large pelvic mass with obstructive uropathy and rectal involvement managed by complete androgen blockade. At 24 months follow-up, the patient has no evidence of progression or metastasis. Aggressive management with multimodality approach combining surgery, radiation and hormonal ablation can result in long disease-free survival in some patients, despite the aggressive nature of this disease.

PMID: 28275015 [PubMed - indexed for MEDLINE]

http://ift.tt/2m9gHwK